SeqLL, Inc. (SQL)
| Market Cap | 46.91M |
| Revenue (ttm) | 329,495 |
| Net Income (ttm) | n/a |
| Shares Out | 11.70M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,123,622 |
| Open | 4.09 |
| Previous Close | 4.02 |
| Day's Range | 3.92 - 4.25 |
| 52-Week Range | 3.30 - 5.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About SQL
SeqLL is an established life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields (e.g. genomics, proteomics, transcriptomics...). Our mission is to empower researchers with improved genetic tools that enable scientists and physicians to better understand the molecular mechanisms of disease and the underlying biological systems. We believe our proprietary sequencing technology platform has critical advantages over existing Next G...
Financial Performance
In 2020, SeqLL's revenue was $329,495, a decrease of -38.20% compared to the previous year's $533,129. Losses were -$1.05 million, -57.74% less than in 2019.
Financial StatementsNews
SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL's tSMS® Platform
Method developed by leading researchers at the Bernstein Laboratory and SeqLL Inc.
SeqLL Inc. Announces Pricing of Upsized $13 Million Initial Public Offering
SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:SQL; SQLLW), a development-stage life sciences...
SeqLL IPO Registration Document (S-1)
SeqLL, Inc. has filed to go public with an IPO on the NASDAQ.